📊 VERU Key Takeaways
Is Veru Inc.. (VERU) a Good Investment?
Veru is a pre-revenue pharmaceutical company with zero reported sales and negative $6.2M operating cash flow, indicating unsustainable cash burn. While the balance sheet is fortress-like with $33M cash and minimal debt providing 5+ year runway, the lack of revenue generation and ongoing operational losses present fundamental concerns about commercialization execution in a competitive sector.
Why Buy Veru Inc.. Stock? VERU Key Strengths
- Exceptional cash position of $33M (69% of total assets) providing substantial runway
- Ultra-conservative balance sheet with 0.05x Debt/Equity and minimal long-term debt ($1.7M)
- Excellent liquidity metrics (Current Ratio 5.16x, Quick Ratio 4.58x) reducing financial distress risk
- Improving loss metrics with net income losses declining 39.9% YoY, indicating operational progress
VERU Stock Risks: Veru Inc.. Investment Risks
- Zero revenue despite positive YoY comparison suggests data inconsistency or severe commercial stagnation typical of failed biotech pipelines
- Negative operating cash flow of $6.2M annually indicates the company is burning through cash reserves with no offsetting revenue
- No insider buying activity in 90 days suggests management lacks confidence in near-term commercialization prospects
- As pharmaceutical company with no revenue, faces high execution risk on pipeline commercialization and regulatory approval
- Current burn rate will deplete cash reserves within 5-7 years if revenue generation is not achieved
Key Metrics to Watch
- Revenue generation (critical inflection point - must show commercial traction)
- Operating cash flow trajectory (must turn positive within 2-3 years to validate business model)
- Cash balance depletion rate relative to clinical/regulatory milestones
- Insider Form 4 filings (buying activity would signal management confidence in pipeline)
Veru Inc.. (VERU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.16x current ratio provides a solid financial cushion.
VERU Profit Margin, ROE & Profitability Analysis
VERU vs Healthcare Sector: How Veru Inc.. Compares
How Veru Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Veru Inc.. Stock Overvalued? VERU Valuation Analysis 2026
Based on fundamental analysis, Veru Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Veru Inc.. Balance Sheet: VERU Debt, Cash & Liquidity
VERU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Veru Inc..'s revenue has declined by 60% over the 5-year period, indicating business contraction. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
VERU Revenue Growth, EPS Growth & YoY Performance
VERU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$7.3M | N/A |
| Q2 2025 | N/A | -$7.9M | N/A |
| Q3 2024 | $3.3M | -$8.3M | N/A |
| Q2 2024 | $4.1M | -$8.3M | $-0.07 |
| Q1 2024 | $2.1M | -$8.3M | $-0.08 |
| Q3 2023 | $3.3M | $6.3M | $0.07 |
| Q2 2023 | $6.6M | -$6.4M | $-0.18 |
| Q1 2023 | $2.5M | -$6.4M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Veru Inc.. Dividends, Buybacks & Capital Allocation
VERU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Veru Inc.. (CIK: 0000863894)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VERU
What is the AI rating for VERU?
Veru Inc.. (VERU) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VERU's key strengths?
Claude: Exceptional cash position of $33M (69% of total assets) providing substantial runway. Ultra-conservative balance sheet with 0.05x Debt/Equity and minimal long-term debt ($1.7M).
What are the risks of investing in VERU?
Claude: Zero revenue despite positive YoY comparison suggests data inconsistency or severe commercial stagnation typical of failed biotech pipelines. Negative operating cash flow of $6.2M annually indicates the company is burning through cash reserves with no offsetting revenue.
What is VERU's revenue and growth?
Veru Inc.. reported revenue of $0.0.
Does VERU pay dividends?
Veru Inc.. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find VERU SEC filings?
Official SEC filings for Veru Inc.. (CIK: 0000863894) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VERU's EPS?
Veru Inc.. has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VERU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Veru Inc.. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VERU stock overvalued or undervalued?
Valuation metrics for VERU: ROE of -14.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VERU stock in 2026?
Our dual AI analysis gives Veru Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VERU's free cash flow?
Veru Inc..'s operating cash flow is $-6.2M, with capital expenditures of $0.0.
How does VERU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -14.4% (avg: 15%), current ratio 5.16 (avg: 2).